uploads///close up _

What Analysts Recommend for Johnson & Johnson after Q4 Results

By

Jan. 30 2019, Updated 12:51 p.m. ET

Stock price movements

On January 28, Johnson & Johnson (JNJ) closed at $128.99, which is 0.63% higher than its previous closing price. The company closed at a premium of 8.74% as compared to its 52-week low price of $118.62 and at a discount of 13.42% as compared to its 52-week high price of $148.99. At the end of January 28, Johnson & Johnson’s market capitalization was $346.11 billion. The company is trading at a trailing PE ratio of 22.99x and a forward PE ratio of 14.21x.

Based on its closing price on January 28, the company reported returns of -1.30% in the last week, 1.80% in the last month, and -6.17% in the last quarter. Johnson & Johnson also reported returns of -0.99% in the last half year, -10.67% in the last year, and -0.05% YTD.

Article continues below advertisement

Based on its closing price on January 28, the broader healthcare sector, represented by the Vanguard Health Care ETF (VHT), reported returns of -2.32% in the last week, 5.34% in the last month, and 0.69% in the last quarter. VHT reported returns of -2.28% in the last half year, -1.52% in the last year, and 2.70% YTD. Johnson & Johnson has significantly underperformed VHT in 2019 YTD.

Analysts’ recommendations and target price

Out of the 19 analysts covering Johnson & Johnson on January 29, four analysts rated the company as a “strong buy,” six analysts have rated the company as a “buy,” eight analysts have rated the company as a “hold,” and one analyst has rated the company as a “sell.”

The 12-month consensus analyst recommendation for Johnson & Johnson on January 29 was a “buy.” The 12-month consensus target price for the company is $144.22, which is 11.81% higher than its last closing price on January 28. The highest, median, and lowest target price estimates for the company are $160, $144.50, and $123, respectively.

In the next article, we will discuss revenue expectations for Johnson & Johnson for fiscal 2019.

Advertisement

More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.